Global Cancer Immunotherapy Drug Discovery Outsourcing Market – Forecast to 2025: A $1.7 Billion Opportunity, Growing at a CAGR of 13.5% – ResearchAndMarkets.com – Business Wire

Source: Global Cancer Immunotherapy Drug Discovery Outsourcing Market – Forecast to 2025: A $1.7 Billion Opportunity, Growing at a CAGR of 13.5% – ResearchAndMarkets.com – Business Wire

DUBLIN–(BUSINESS WIRE)–The “Cancer
Immunotherapy Drug Discovery Outsourcing Market Analysis Report By Drug,
By Service, By Cancer Type (Lung, Breast, Colorectal, Melanoma,
Prostate, Pancreatic), And Segment Forecasts, 2018 – 2025”
report has been added to ResearchAndMarkets.com’s
offering.

The global cancer immunotherapy drug discovery outsourcing market size
is projected to reach USD 1.7 Billion by 2025, rising at a CAGR of 13.5%
during the forecast period.

Increasing prevalence of cancer and rising mortality associated with
cancer, along with growing development in the field of cancer
immunotherapy, are anticipated to stimulate the growth of the market.

In order to maintain pace with increasing competition in the cancer
therapeutics industry, pharmaceutical companies spend 2.5% more than
other high tech industries in the in-house R&D. Hence, they are swiftly
shifting towards outsourcing of drug discovery in order to achieve lower
in-house R&D costs.

Additionally, favorable tax credit allows pharmaceutical companies to
appropriately plan their global projects with a reputed CRO and
therefore, receive benefits and reduce problems associated with taxation
authorities or other bodies administering such incentive programs.

Several new molecules for cancer immunotherapy and new immunotherapeutic
options, such as tumor infiltrating lymphocytes, check point inhibitors
immunomodulators, and CAR-T cell therapy, have been introduced. Some are
in the pipeline and are being tested for their ability to provide better
cancer treatment

Further Key Findings From the Report Suggest

• Monoclonal antibodies emerged as the largest segment in 2017 because
  of increasing regulatory approvals and higher efficacy
• Target identification and validation accounted for the largest share
  in the global market owing to higher costs incurred and increased
  investments in new drug development
• North America dominated the market with the largest share in 2017.
  Rising incidence of cancer and increasing demand for novel
  technologies are facilitating the dominance of the region during the
  forecast period
• Some of the key players are Covance, Inc.; Explicyte; Aquila
  BioMedical; Horizon Discovery Group PLC; Crown Bioscience, Inc.;
  Promega Corporation; HD Biosciences Co., Ltd.; BPS Bioscience, Inc.;
  Genscript Biotech Corporation; DiscoverX Corporation; Celentyx Ltd.;
  ImmunXperts SA; Personalis, Inc.; STC Biologics; and Molecular
  Imaging, Inc. dominated the cancer immunotherapy drug discovery
  outsourcing market

Topics Covered

Chapter 1 Methodology and Scope

1.1 Research Methodology

1.2 Research Scope and Assumptions

Chapter 2 Executive Summary

2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

3.1 Market Segmentation

Chapter 4 Industry Outlook

4.1 Market Variable Analysis

4.1.1 Increasing in-house R&D costs

4.1.2 Increasing adoption of advanced technologies

4.1.3 Mergers and acquisitions

4.1.4 Tax credit

4.2 Market Restraint Analysis

4.2.1 Quality issues involved with drug discovery CRO services

4.2.2 Intellectual property right issues

4.3 Porter’s Five Forces Analysis

Chapter 5 Drug Type Business Analysis

5.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Drug
Movement Analysis

5.2 Monoclonal Antibodies

5.3 Immunomodulators

5.4 Cancer Vaccines and Oncolytic Therapies

5.5 Others

Chapter 6 Service Business Analysis

6.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Service
Movement Analysis

6.2 Target Identification and Validation

6.3 Lead screening and Characterization

6.4 Cell based Assays

Chapter 7 Cancer Business Analysis

7.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Cancer
Movement Analysis

7.2 Lung Cancer

7.3 Breast Cancer

7.4 Colorectal Cancer

7.5 Melanoma

7.6 Prostate Cancer

7.7 Head and Neck Cancer

7.8 Ovarian Cancer

7.9 Pancreatic Cancer

Chapter 8 Regional Business Analysis

8.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Regional
Movement Analysis

8.2 North America

8.3 Europe

8.4 Asia Pacific

8.5 Latin America

8.6 Middle East & Africa

Chapter 9 Company Profile

9.1 Strategy Framework

9.2 Explicit Immuno-oncology

9.3 Aquila Biomedical

9.4 Horizon Discovery Group PLC

9.5 Crown Bioscience Inc.

9.6 Promega Corporation

9.7 HD Biosciences Co. Ltd.

9.8 BPS Biosciences Inc.

9.9 Gen Script Biotech Corporation

9.10 Celentyx Ltd.

9.11 ImmuneXperts S.A.

9.12 Personalis

9.13 STC Biologics

9.14 Molecular Imaging Inc. (MI Bioresearch Inc.)

9.15 Covance Inc.

For more information about this report visit https://www.researchandmarkets.com/research/q767f5/global_cancer?w=4

Published at Wed, 06 Mar 2019 18:35:00 +0000